Consensus ANI Pharmaceuticals, Inc.

Equities

ANIP

US00182C1036

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-23 pm EDT			5-day change	1st Jan Change
66.14 ^USD	+0.79%		+0.88%	+19.95%

Apr. 17	Ani Pharmaceuticals Insider Sold Shares Worth $1,500,589, According to a Recent SEC Filing	MT
Apr. 09	ANI Pharmaceuticals, Inc. Announces the Launch of Baclofen Oral Suspension	CI

Evolution of the average Target Price on ANI Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

f9200a5.5gC1BSc_5WPeSfqUniJ4ISMwCKlgMJSDGPLuu877KZU.hGqFXBNujFC5PYLM1nUKa3peQv8ycszLSpuIjZycRcyIcvw8YljRCe0Qwg~de67ee515de7c9301f80ae21819afdea

Analyst Recommendations on ANI Pharmaceuticals, Inc.

Ani Pharmaceuticals Insider Sold Shares Worth $1,500,589, According to a Recent SEC Filing	Apr. 17	MT
Ani Pharmaceuticals Insider Sold Shares Worth $1,345,000, According to a Recent SEC Filing	Apr. 03	MT
Capital One Initiates ANI Pharmaceuticals at Overweight Rating	Mar. 15	MT
Guggenheim Adjusts ANI Pharmaceuticals' Price Target to $77 From $70, Maintains Buy Rating	Mar. 05	MT
HC Wainwright Adjusts Price Target on ANI Pharmaceuticals to $83 From $73, Maintains Buy Rating	Mar. 04	MT
Truist Securities Raises Price Target on ANI Pharmaceuticals to $80 From $72, Maintains Buy Rating	Mar. 01	MT
Truist Securities Adjusts Price Target on ANI Pharmaceuticals to $72 From $70, Maintains Buy Rating	Feb. 16	MT
HC Wainwright Adjusts Price Target on ANI Pharmaceuticals to $73 From $60, Maintains Buy Rating	23-08-22	MT
Guggenheim Adjusts ANI Pharmaceuticals' Price Target to $62 From $59, Keeps Buy Rating	23-07-27	MT
Truist Adjusts ANI Pharmaceuticals' Price Target to $60 From $52, Keeps Buy Rating	23-07-21	MT
Guggenheim Adjusts Price Target on ANIP to $59 From $55, Maintains Buy Rating	23-05-09	MT
Truist Securities Adjusts Price Target on ANI Pharmaceuticals to $52 From $50, Maintains Buy Rating	23-05-09	MT
Raymond James Adjusts Price Target on ANI Pharmaceuticals to $49 From $48, Maintains Outperform Rating	23-05-09	MT
HC Wainwright Adjusts Price Target on ANI Pharmaceuticals to $60 From $53, Keeps Buy Rating	23-05-09	MT
Cantor Fitzgerald Adjusts ANI Pharmaceuticals Price Target to $42 From $40, Maintains Neutral Rating	23-05-08	MT
HC Wainwright Adjusts Price Target on ANI Pharmaceuticals to $53 From $50, Keeps Buy Rating	23-03-13	MT
Cosette Pharmaceuticals, Inc. Launches Betaine Anhydrous Powder, AB-rated to Cystadane (Betaine Anhydrous for Oral Solution)	23-03-02	CI
HC Wainwright Starts ANI Pharmaceuticals at Buy With $50 Price Target	22-09-07	MT
S&P Revises ANI Pharmaceuticals Outlook To Stable From Positive On Increased Expenses; 'B+' Ratings Affirmed	22-08-29	MT
Raymond James Adjusts ANI Pharmaceuticals' Price Target to $47 From $65, Keeps Outperform Rating	22-03-16	MT
Raymond James Adjusts ANI Pharmaceuticals' Price Target to $65 from $60, Keeps Outperform Rating	21-11-02	MT
Truist Securities Starts ANI Pharmaceuticals at Buy With $70 Price Target	21-11-02	MT
ANI PHARMACEUTICALS : Raymond James Adjusts Price Target on ANI Pharmaceuticals to $60 From $40, Maintains Outperform Rating	21-05-10	MT
ANI Pharmaceuticals, Inc. Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2016; Provides Earnings Guidance for the Year Ending December 31, 2016 and Effective Tax Rate Guidance for the Fourth Quarter Ending December 31, 2016	16-11-03	CI